These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26516934)

  • 41. How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver.
    Socinski MA
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):759-765. PubMed ID: 29040255
    [No Abstract]   [Full Text] [Related]  

  • 42. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Monoclonal antibodies in the diagnosis and therapy of lung cancer].
    Campobasso N; Dammacco F
    Recenti Prog Med; 1991 Dec; 82(12):642-51. PubMed ID: 1667710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunotherapies and targeted therapies in medical oncology].
    Rousseau B; Champiat S; Loirat D; Arrondeau J; Lemoine N; Soria JC
    Bull Cancer; 2014 Jan; 101(1):31-9. PubMed ID: 24333964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
    Phillips T; Simmons P; Inzunza HD; Cogswell J; Novotny J; Taylor C; Zhang X
    Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):541-9. PubMed ID: 26317305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
    Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
    Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospects for the management of non-small-cell carcinoma of the lung with monoclonal antibodies.
    Stein R; Goldenberg DM
    Chest; 1991 Jun; 99(6):1466-76. PubMed ID: 1645244
    [No Abstract]   [Full Text] [Related]  

  • 48. Cytokine immunotherapy of non-small cell lung cancer.
    Dubinett SM; Kradin RL
    Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
    [No Abstract]   [Full Text] [Related]  

  • 49. Selecting patients for immune checkpoint inhibition in lung cancer.
    Garon EB
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):490-2. PubMed ID: 26351808
    [No Abstract]   [Full Text] [Related]  

  • 50. Next steps for cancer immune therapy.
    Cancer Discov; 2015 Mar; 5(3):221-2. PubMed ID: 25710919
    [No Abstract]   [Full Text] [Related]  

  • 51. Understanding immunotherapy for the treatment of non-small cell lung cancer.
    Thomas R
    Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Non-small cell lung cancer: news from immunotherapy].
    Reinmuth N; Heigener DF; Reck M
    Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immune alterations in lung cancer - the new therapeutic approach].
    Domagała-Kulawik J; Osińska I
    Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    Khunger M; Calabrese C; Kontzias A; Velcheti V
    J Thorac Oncol; 2017 Sep; 12(9):e147-e149. PubMed ID: 28838717
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
    Printz C
    Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.